Harborside


AXIM Biotechnologies, Inc.

AXIM


Canadian symbol: AXIM
US symbol: AXIM

Currency in USD

Valuation Measures

Market Cap (intraday) 589.42M
Enterprise Value 399.2M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)1,881.55
Price/Book (mrq)83.88
Enterprise Value/Revenue 32,087.43
Enterprise Value/EBITDA 7-16.67

Trading Information

Stock Price History

Beta (5Y Monthly) -0.11
52-Week Change 30.00%
S&P500 52-Week Change 334.98%
52 Week High 31.2200
52 Week Low 30.3940
50-Day Moving Average 30.6458
200-Day Moving Average 30.7122

Share Statistics

Avg Vol (3 month) 3139.06k
Avg Vol (10 day) 3123.33k
Shares Outstanding 5133.26M
Implied Shares Outstanding 6N/A
Float 39.59M
% Held by Insiders 155.16%
% Held by Institutions 10.00%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Jun. 29, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-13,906.25%

Management Effectiveness

Return on Assets (ttm)-38.56%
Return on Equity (ttm)-906.08%

Income Statement

Revenue (ttm)47.52k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -5.95M
Net Income Avi to Common (ttm)-9.23M
Diluted EPS (ttm)-0.0770
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)202.19k
Total Cash Per Share (mrq)0
Total Debt (mrq)6.12M
Total Debt/Equity (mrq)590.00
Current Ratio (mrq)0.30
Book Value Per Share (mrq)0.01

Cash Flow Statement

Operating Cash Flow (ttm)-2.57M
Levered Free Cash Flow (ttm)-1.87M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
AXIM
AXIM Biotechnologies
2 months ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
55.16%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by AXIM Biotechnologies, Inc.


AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development

AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development

SAN DIEGO, Sept. 15, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19, dry eye disease (DED) and Cancer, today announced that it has appointed Jeffrey A. Busby to Senior Vice President – Business Development. Mr. Busby brings more t... Read More...
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

SAN DIEGO, Aug. 30, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the Company’s manufacturing partner Empowered Diagnostics has filed an amended emergency use a... Read More...
AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

SAN DIEGO, May 03, 2021 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today a new ELISA test that measures levels of neutralizing antibodies against six common variants of SARS-CoV-2 virus. The Co... Read More...
Coming Soon.

Delayed data (1h)


Share this page